Skip to main content

Advertisement

SpringerLink
Log in

Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine

  • Letter to the Editor
  • Published:
Leukemia Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1
Figure 2

References

  1. Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A et al. Mutation in TET2 in myeloid cancers. N Engl J Med 2009; 360: 2289–2301.

    Article  Google Scholar 

  2. Tefferi A, Lim KH, Abdel-Wahab O, Lasho TL, Patel J, Patnaik MM et al. Detection of mutant TET2 in myeloid malignancies other than myeloproliferative neoplasms: CMML, MDS, MDS/MPN and AML. Leukemia 2009; 23: 1343–1345.

    Article  CAS  Google Scholar 

  3. Abdel-Wahab O, Mullally A, Hedvat C, Garcia-Manero G, Patel J, Wadleigh M et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009; 114: 144–147.

    Article  CAS  Google Scholar 

  4. Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS et al. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 2010; 468: 839–843.

    Article  CAS  Google Scholar 

  5. Voso MT, Santini V, Finelli C, Musto P, Pogliani E, Angelucci E et al. Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes. Clin Cancer Res 2009; 15: 5002–5007.

    Article  CAS  Google Scholar 

  6. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, Santini V, Finelli C, Giagounidis A et al. International Vidaza High-Risk MDS Survival Study Group.v Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 2009; 10: 223–232.

    Article  CAS  Google Scholar 

  7. Fabiani E, Leone G, Giachelia M, D’alo F, Greco M, Criscuolo M et al. Analysis of genome-wide methylation and gene expression induced by 5-aza-2′-deoxycytidine identifies BCL2L10 as a frequent methylation target in acute myeloid leukemia. Leuk Lymphoma 2010; 51: 2275–2284.

    Article  CAS  Google Scholar 

  8. Kosmider O, Gelsi-Boyer V, Cheok M, Grabar S, Della-Valle V, Pic F et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009; 114: 3285–3291.

    Article  CAS  Google Scholar 

  9. Smith AE, Mohamedali AM, Kulasekararaj A, Lim Z, Gäken J, Lea NC et al. Next-generation sequencing of the TET2 gene in 355 MDS and CMMLpatients reveals low abundance mutant clones with early origins, but indicates no definite prognostic value. Blood 2010; 116: 3923–3932.

    Article  CAS  Google Scholar 

  10. Itzykson R, Kosmider O, Cluzeau T, Mansat-De Mas V, Dreyfus F, Beyne-Rauzy O et al. Impact of TET2 mutations on responserate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011; 25: 1147–1152.

    Article  CAS  Google Scholar 

  11. Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C, Testoni N et al. Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS. Proc Natl Acad Sci U S A 2009; 106: 16811–16816.

    Article  Google Scholar 

  12. Höglund A, Nilsson LM, Forshell LP, Maclean KH, Nilsson JA . Myc sensitizes p53-deficient cancer cells to the DNA-damaging effects of the DNA methyltransferase inhibitor decitabine. Blood 2009; 113: 4281–4288.

    Article  Google Scholar 

  13. Xu JD, Furuya T, Cao XX, Liu XL, Li QQ, Wang WJ et al. Loss of BCL2L10 protein expression as prognostic predictor for poor clinical outcome in gastric carcinoma. Histopathology 2010; 57: 814–824.

    Article  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from Associazione Italiana Ricerca sul Cancro (GL and CM). We would like to acknowledge all Gimema centers who took part to the MDS0205 clinical trial.

Author information

Authors and Affiliations

  1. Istituto di Ematologia, Universita’ Cattolica S. Cuore, Rome, Italy

    M T Voso, E Fabiani, M Greco, M Criscuolo, L Fianchi, S Hohaus & G Leone

  2. Gimema Data Center, for the GIMEMA AL WP–Commissione MDS, Rome, Italy

    A Piciocchi & M Vignetti

  3. Hematology, University of Perugia, Perugia, Italy

    C Matteucci, L Brandimarte & C Mecucci

  4. Istituto di Ematologia ‘Seràgnoli’, Universita’ di Bologna, Bologna, Italy

    C Finelli

  5. Dipartimento di Medicina Interna, Universita’ di Milano-Bicocca, Monza, Italy

    E Pogliani

  6. Unità Operativa Ematologia e Centro Trapianti, Ospedale Oncologico di Riferimento Regionale ‘ Armando Businco’, Cagliari, Italy

    E Angelucci

  7. Ematologia, Ospedale Civico, Pescara, Italy

    G Fioritoni

  8. Dipartimento Onco-Ematologico, IRCCS ‘Centro di Riferimento Oncologico di Basilicata’, Rionero in Vulture, Pz, Italy

    P Musto

  9. UF Ematologia, AOU Careggi, Università di Firenze, Firenze, Italy

    V Santini

Authors
  1. M T Voso
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E Fabiani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Piciocchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. C Matteucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. L Brandimarte
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Finelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E Pogliani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E Angelucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Fioritoni
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. P Musto
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Greco
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. M Criscuolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. L Fianchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Vignetti
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. V Santini
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. S Hohaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. C Mecucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. G Leone
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M T Voso.

Ethics declarations

Competing interests

MTV, PM, CF, VS and GL received ‘Honoraria’ from Celgene as speakers. The other authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Leukemia website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Voso, M., Fabiani, E., Piciocchi, A. et al. Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia 25, 1910–1913 (2011). https://doi.org/10.1038/leu.2011.170

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2011.170

  • Springer Nature Limited

This article is cited by

Search

Navigation